WeightRx review
Tirzepatide costs $83 and semaglutide costs $250, which reverses the usual order.
The verdict
WeightRx publishes $83 a month for compounded tirzepatide and $250 for semaglutide, read August 2026. Both figures appear on the homepage. The tirzepatide line is the cheaper of the two.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- From
- $83/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
WeightRx sells both molecules by injection. Two figures are published together. The dual agonist is priced below the single one.
Who writes the prescription, and what do they see?
A prescription precedes shipping. The homepage carries the prices. No clinician is described.
Tirzepatide normally carries a premium of fifty to a hundred dollars. Here it is a third of the semaglutide figure, and nothing on the pages explains the inversion.
What happens when the dose goes up?
Nothing is published about dose on either line. With the molecule pricing already inverted, a reader has no way to check whether the pattern holds as the dose rises.
What the price includes
Six months of tirzepatide at $83 is $498 and semaglutide at $250 is $1,500. A three-fold gap in the unusual direction is worth confirming with the seller before ordering, because a transposition would explain it too.
What it claims, and what it cites
Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named.
Where it holds up, and where it does not
- Strength: Both figures published on one page
- Strength: Tirzepatide is unusually cheap here
- Strength: Both molecules are offered
- Limitation: The molecule pricing is inverted
- Limitation: Nothing explains the inversion
- Limitation: No milligram dose published
- Limitation: No state coverage list is recorded
What the evidence says about this kind of treatment
The assessment above is about WeightRx. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader wanting tirzepatide who will confirm the figure before ordering.
- Wrong for
- A reader shopping the semaglutide line on price.
How WeightRx compares
| Seller | Who it suits | Go |
|---|---|---|
| VyrarX | Readers who will ask what maintenance costs before starting | See VyrarX → |
| Readers in any jurisdiction wanting a flat rate with little to decide | See YourHealthRx → | |
| Wellspring Longevity Clinic | Readers who want a custom blend and will ask what theirs costs | See Wellspring Longevity Clinic → |
More GLP-1 telehealth sellers reviews: Somira HealthSprout HealthStackMDSumbare WellnessSunlightSuperior Remedies
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- Why is tirzepatide cheaper?
- Nothing on the pages explains it. Tirzepatide is $83 and semaglutide $250, which reverses the usual order.
- Should I confirm it?
- Yes. A three-fold gap in the unusual direction is worth checking with the seller before ordering.
- What dose do these buy?
- No milligram figure is published beside either price.
- Is WeightRx expensive compared with other GLP-1 telehealth sellers?
- WeightRx publishes a starting figure of $83/mo. Across the 169 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $369 with a median of $179, which puts WeightRx below the median, toward the cheaper end. The other 11 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.